文献速递细胞病理与分子病理

Afirma基因表达分类器在重复不确定甲状腺结节中的评估

Evaluation of the Afirma Gene Expression Classifier in Repeat Indeterminate Thyroid Nodules.
PubMed 文献 · Arch Pathol Lab Med · 2017-05-03

Afirma将50%结节判为可疑,手术切除后这些结节恶性率为35%,阳性预测值仅35%,低于机构历史Bethesda III(11%)和IV(23%)的恶性率。

要点

  • Afirma在重复不确定甲状腺结节中阳性预测值低(35%)。
  • 可疑结节手术切除后65%为良性,恶性仅35%。
  • Afirma良性结节手术切除后均为良性。

核心结论

  • Afirma在不确定甲状腺结节中阳性预测值低,与既往报道一致。

主要发现

  • 良性结节中3个(6%)手术切除,最终病理均为良性。

关键数值与推荐

  • Afirma可疑结节手术切除恶性率35%,机构历史Bethesda III结节恶性率11%、Bethesda IV结节恶性率23%。

临床怎么用

  • Afirma可疑结果需谨慎解读,因其阳性预测值低,可能需结合其他临床信息决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: - Molecular testing in indeterminate thyroid nodules is a rapidly evolving field with variable reported outcomes. OBJECTIVE: - To report our experience at a tertiary thyroid referral center with the Afirma Gene Expression Classifier (Veracyte, San Francisco, California) in repeat fine-needle aspirations of thyroid nodules with a previous indeterminate cytologic result. DESIGN: - Results of cytopathology and the Afirma test were collected from August 2013 to March 2015, as were diagnoses from surgical resection when performed. RESULTS: - One hundred and fifteen thyroid nodules were evaluated by Afirma. The fine-needle aspiration diagnostic categories for these nodules were 100 (87%) Bethesda III, 10 (9%) Bethesda IV, 3 (2%) Bethesda II, 1 (1%) Bethesda V, and 1 (1%) Bethesda I. Afirma results for 52 of the nodules (45%) were benign, 57 (50%) were suspicious, and 6 (5%) specimens yielded no result because of low messenger RNA content. Three of the benign nodules (6%) were treated surgically, and all were benign on final surgical pathology. Forty-six (81%) of the suspicious nodules were treated surgically; final surgical pathology revealed 30 (65%) were benign and 16 (35%) malignant, yielding a positive predictive value of 35%. CONCLUSIONS: - In our experience, 50% of the indeterminate nodules were classified as suspicious by Afirma, with a 35% rate of malignancy in these nodules at surgical resection, in comparison with a historical rate of malignancy at our institution of 11% for Bethesda III nodules and 23% for Bethesda IV. Our use of Afirma is consistent with prior reports in that it has a low positive predictive value in indeterminate thyroid nodules.

来源:Arch Pathol Lab Med,查看原文。版权归原作者所有。

引用

  1. Harrison G, Sosa JA, Jiang X, et al. Evaluation of the Afirma Gene Expression Classifier in Repeat Indeterminate Thyroid Nodules. Arch Pathol Lab Med. 2017. PMID: 28467214. doi:10.5858/arpa.2016-0328-OA

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。